Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 525-534
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.525
Chemotherapy drug classes | Examples |
Platinum-containing agents | (Cisplatin, carboplatin, oxaliplatin) |
Folate antagonists | (Methotrexate, pemetrexed) |
Pyrimidine compounds | (Fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine) |
Purine analogues | (Mercaptopurine, fludarabine, cladribine, clofarabine) |
Alkylating agents | (Cyclophosphamide, ifosfamide, melphalan, bendamustine, busulfan) |
Anthracyclines | (Daunorubicin, doxorubicin, epirubicin, idarubicin, bleomycin) |
Topoisomerases | (Topotecan, etoposide, irinotecan) |
Cytidine analogues | (Azacytidine, decitabine) |
Immunosuppressants | (Tacrolimus, cyclosporine) |
Immunomodulatory drugs | (Ienalidomide, thalidomide) |
Mitotic inhibitors | (Paclitaxel, docetaxel, vinblastine, vincristine) |
Hormonal therapies | (Tamoxifen) |
Targeted therapies other than rituximab | (e.g., cetuximab, bortezomib, alemtuzumab) |
- Citation: Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/525.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.525